Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is a Healthcare company (Biotechnology) with a market capitalization of $633M. The Maz Rating grades it against the other companies in its sector.
Olema Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.22, Olema Pharmaceuticals, Inc. trades at 2.0x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -53.7%, return on invested capital of -67.9% and a free cash flow yield of -28.2%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 6.12. Over the past 52 weeks the share price ranged from $6.24 to $36.26, with a beta of 2.02.
Olema Pharmaceuticals, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 9 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Olema Pharmaceuticals, Inc. (OLMA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.33% / 30% · (Cash+Inv) / Mkt Cap (36m) 45.7% / 30% · Interest income / Revenue 405400000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.33% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 45.7% / 33% · Receivables / Mkt Cap (36m) 0.37% / 49% · Interest income / Revenue 405400000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.33% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 45.7% / 33.33% · Receivables / Mkt Cap (24m) 0.37% / 33.33% · Interest income / Revenue 405400000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.29% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 94.7% / 33.33% · Receivables / Avg Assets (4Q) 0.54% / 33.33% · Interest income / Revenue 405400000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.68% / 33.33% · (Cash+ST Inv) / Total Assets 93.8% / 33.33% · (Cash+Recv) / Total Assets 94.6% / 33.33% · Interest income / Revenue 405400000.0% / 5% | Fail |
No. As of September 2026, Olema Pharmaceuticals, Inc. (OLMA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Olema Pharmaceuticals, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 405400000.0% of each dividend: Olema Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.